MAGEA4 and neoplasm: In the open-label, Phase 2, SPEARHEAD-1 trial, patients with advanced SS and MLPS, positive for HLA-A*02 and MAGE-A4 tumour expression received afamitresgene autoleucel (afami-cel), an autologous TCR T-cell therapy after lymphodepleting chemotherapy containing fludarabine and cyclophosphamide.